of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalfentanyl intranasal, thioridazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalfentanyl transdermal, thioridazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalfentanyl transmucosal, thioridazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fexinidazolefexinidazole and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.fluconazolethioridazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fluoxetinefluoxetine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluphenazinefluphenazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.fluvoxaminefluvoxamine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated.fluvoxamine and thioridazine both increase QTc interval. Contraindicated.formoterolthioridazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glasdegibthioridazine and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.haloperidolhaloperidol will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.thioridazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.histrelinhistrelin increases toxicity of thioridazine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.hydrocodonehydrocodone, thioridazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).hydroxychloroquine sulfatehydroxychloroquine sulfate and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.imatinibimatinib will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.imipraminethioridazine and imipramine both increase QTc interval. Avoid or Use Alternate Drug.inotuzumabinotuzumab and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.itraconazolethioridazine and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.ivosidenibivosidenib and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.ketoconazolethioridazine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.lefamulinlefamulin and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.levodopathioridazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.levodopa inhaledthioridazine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Phenothiazine/1st generation antipsychotics inhibit dopamine D2 receptors in varying degrees.levoketoconazolethioridazine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.lisuridethioridazine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.lofepraminethioridazine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.lumefantrinelumefantrine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.thioridazine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.macimorelinmacimorelin and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.maprotilinethioridazine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.maravirocmaraviroc will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.marijuanamarijuana will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.mefloquinemefloquine increases toxicity of thioridazine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.methyl aminolevulinatethioridazine, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.methyldopathioridazine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.metoclopramide intranasalthioridazine will increase the level or effect of metoclopramide intranasal by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of metoclopramide intranasal and strong CYP2D6 inhibitors is not recommended since the metoclopramide intranasal dose cannot be adjusted.thioridazine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.thioridazine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.metoprololmetoprolol, thioridazine. Either increases levels of the other by decreasing metabolism. Contraindicated. Not all beta blockers share this interaction (e.g., atenolol, nadolol, sotalol do not interact).mobocertinibmobocertinib and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.moxifloxacinthioridazine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.nilotinibnilotinib will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.thioridazine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.nortriptylinethioridazine and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.octreotidethioridazine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.octreotide (Antidote)thioridazine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.olopatadine intranasalthioridazine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. ondansetronthioridazine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.panobinostatthioridazine and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.parecoxibparecoxib will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.paroxetineparoxetine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.thioridazine will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.thioridazine and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.perphenazineperphenazine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.perphenazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.pimavanserinpimavanserin and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia.pitolisantthioridazine and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.pramipexolethioridazine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.prochlorperazineprochlorperazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.promazinepromazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.promethazinepromethazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.propafenonepropafenone will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.thioridazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.propranololthioridazine will increase the level or effect of propranolol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Due to the potential for significant, possibly life-threatening, proarrhythmic effects, concurrent administration of thioridazine and propranolol is contraindicated.propranolol, thioridazine. Either increases levels of the other by decreasing metabolism. Contraindicated. Not all beta blockers share this interaction (e.g., atenolol, nadolol, sotalol do not interact).protriptylinethioridazine and protriptyline both increase QTc interval. Avoid or Use Alternate Drug.quinacrinequinacrine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.quinidinequinidine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.quinidine, thioridazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive cardiac effects.ranolazineranolazine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.ribociclibribociclib and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.ritonavirritonavir will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.ropinirolethioridazine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamidethioridazine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.selinexorselinexor, thioridazine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sertralinesertraline will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.sodium oxybatethioridazine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tipranavirtipranavir will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.trazodonethioridazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.tretinointhioridazine, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.tretinoin topicalthioridazine, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.trifluoperazinethioridazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.trimipraminethioridazine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.triptorelintriptorelin increases toxicity of thioridazine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.umeclidinium bromide/vilanterol inhaledthioridazine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vandetanibthioridazine, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.vemurafenibvemurafenib increases levels of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with agents with narrow therapeutic windows is not recommended as vemurafenib may alter their concentrations. If coadministration cannot be avoided, use caution and consider dose reduction of concomitant CYP2D6 substrate drug. Combination may increase risk QT prolongation.venlafaxinevenlafaxine will increase the